Research location
Oshawa
Canada
Advertisement
Research activity in Oshawa
CanadaCureCurrent currently publishes aggregate city-level research activity for this location: 20 trials and 22 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Oshawa
20 linked trials · page 1 of 1The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)NCT03767543 · 2019-03-11 · 1 site observation
COMPLETED
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19 · 2 site observations
TERMINATED
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934 · 2017-06-13 · 1 site observation
COMPLETED
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus PatientsNCT02401243 · 2015-03-01 · 1 site observation
COMPLETED
LUMINIST: LUng Cancer Molecular Insights Non Interventional StudyNCT02300831 · 2014-12-01 · 1 site observation
COMPLETED
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung CancerNCT01500720 · 2012-03-01 · 1 site observation
COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime InsulinNCT01499082 · 2011-12-01 · 1 site observation
COMPLETED
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerNCT01308580 · 2011-04-01 · 1 site observation
COMPLETED
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyNCT01186861 · 2011-03-04 · 1 site observation
COMPLETED
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinNCT01285609 · 2011-01-16 · 1 site observation
COMPLETED
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)NCT01147250 · 2010-06-01 · 1 site observation
COMPLETED
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)NCT01082549 · 2010-03-01 · 1 site observation
COMPLETED
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerNCT00651326 · 2008-06-02 · 1 site observation
TERMINATED
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · 2007-06-01 · 1 site observation
UNKNOWN
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 DiabetesNCT00469586 · 2007-04-26 · 1 site observation
TERMINATED
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)NCT00404547 · 2006-11-01 · 2 site observations
COMPLETED
Tamoxifen in Treating Women With High-Risk Breast CancerNCT00002542 · 1993-07-20 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.